Skip to main
SIBN
SIBN logo

SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE Inc (SIBN) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

SI-BONE Inc. has demonstrated a substantial financial performance in the second quarter of 2025, with revenue increasing approximately 23% year-over-year to $46.4 million, reflecting strong demand for its medical device products. The company's gross margin also showed improvement, rising around 80 basis points year-over-year to 79.8%, indicating enhanced efficiency in its operations. Additionally, an increase of approximately 25% in the number of surgeons utilizing SI-BONE's products further underscores the company's growing market penetration and potential for sustained revenue growth.

Bears say

The financial outlook for SI-BONE Inc is hindered by a stagnating global spine market, which has encountered pricing pressures and procedural challenges that have resulted in growth rates limited to the low single digits. Moreover, the potential shift in reimbursement practices by payors toward competitive products poses a significant risk to SI-BONE's market share in sacroiliac joint fusion procedures, further jeopardizing its top-line revenue. Continued expectations of prevailing market headwinds could exacerbate these issues, leading to ongoing constraints on the company's financial performance.

SI-BONE Inc (SIBN) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SI-BONE Inc (SIBN) Forecast

Analysts have given SI-BONE Inc (SIBN) a Buy based on their latest research and market trends.

According to 4 analysts, SI-BONE Inc (SIBN) has a Buy consensus rating as of Oct 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SI-BONE Inc (SIBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.